| Literature DB >> 28570825 |
Marcos Guilherme da Cunha1,2, Erivan Schnaider Ramos-Junior3,4, Marcelo Franchin1, Thaise Mayumi Taira3, John A Beutler2, Gilson Cesar Nobre Franco5, Masaharu Ikegaki6, Severino Matias de Alencar7, Sandra Yasuyo Fukada3, Pedro Luiz Rosalen1.
Abstract
Bone-loss-related diseases such as rheumatoid arthritis, osteomyelitis, osteoporosis, and periodontitis are associated with high rates of morbidity worldwide. These disorders are characterized by an imbalance between the formation and activity of osteoblasts and osteoclasts, leading to bone loss. In this context, we evaluated the effect of cinnamoyloxy-mammeisin (CNM), an anti-inflammatory coumarin found in Melipona scutellaris geopropolis, on key targets related to bone remodeling. In the present study we investigated the in vitro effects of CNM on osteoclast differentiation and M-CSF+RANKL-induced osteoclastogenic marker expression. Additionally, the interference of CNM treatment on osteoclast activity was evaluated by zymography and resorption area. Finally, we assessed the capacity of the compound to mitigate alveolar bone loss in vivo in experimental murine periodontitis induced by Porphyromonas gingivalis. We observed that treatment with CNM impaired osteoclast differentiation, as evidenced by a reduced number of tartrate-resistant acid-phosphatase-positive multinucleated cells (TRAP+) as well as the expression of osteoclastogenic markers upon M-CSF+RANKL-induced stimulation. Similarly, we observed reduced gelatinolytic and resorption capacity in M-CSF+RANKL-induced cells in vitro. Lastly, CNM attenuated alveolar bone loss in an experimental murine periodontitis model. These findings indicate that CNM may be considered a promising treatment for bone loss diseases.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28570825 PMCID: PMC7367504 DOI: 10.1021/acs.jnatprod.7b00194
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050